JP2001510338A - ベクターとして鳥類の感染性喉頭気管炎ウイルスを用いた鳥類用組換え生ワクチン - Google Patents
ベクターとして鳥類の感染性喉頭気管炎ウイルスを用いた鳥類用組換え生ワクチンInfo
- Publication number
- JP2001510338A JP2001510338A JP52739498A JP52739498A JP2001510338A JP 2001510338 A JP2001510338 A JP 2001510338A JP 52739498 A JP52739498 A JP 52739498A JP 52739498 A JP52739498 A JP 52739498A JP 2001510338 A JP2001510338 A JP 2001510338A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- recombinant
- sequence
- plasmid
- iltv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 title claims abstract description 60
- 229960005486 vaccine Drugs 0.000 title claims abstract description 38
- 241000271566 Aves Species 0.000 title claims description 19
- 230000037431 insertion Effects 0.000 claims abstract description 41
- 238000003780 insertion Methods 0.000 claims abstract description 41
- 239000002773 nucleotide Substances 0.000 claims abstract description 19
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 19
- 108020004705 Codon Proteins 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 241000700605 Viruses Species 0.000 claims description 53
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 27
- 101000584877 Clostridium pasteurianum Putative peroxiredoxin in rubredoxin operon Proteins 0.000 claims description 23
- 101000618323 Enterobacteria phage T4 Uncharacterized 7.3 kDa protein in mobB-Gp55 intergenic region Proteins 0.000 claims description 23
- 101001056912 Saccharopolyspora erythraea 6-deoxyerythronolide-B synthase EryA1, modules 1 and 2 Proteins 0.000 claims description 23
- 101001056914 Saccharopolyspora erythraea 6-deoxyerythronolide-B synthase EryA3, modules 5 and 6 Proteins 0.000 claims description 23
- 101000819251 Staphylococcus aureus Uncharacterized protein in ileS 3'region Proteins 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 22
- 101000758020 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized aminotransferase BpOF4_10225 Proteins 0.000 claims description 21
- 101000744710 Clostridium pasteurianum Uncharacterized glutaredoxin-like 8.6 kDa protein in rubredoxin operon Proteins 0.000 claims description 21
- 101000653283 Enterobacteria phage T4 Uncharacterized 11.5 kDa protein in Gp31-cd intergenic region Proteins 0.000 claims description 21
- 101000618324 Enterobacteria phage T4 Uncharacterized 7.9 kDa protein in mobB-Gp55 intergenic region Proteins 0.000 claims description 21
- 101000961876 Pyrococcus woesei Uncharacterized protein in gap 3'region Proteins 0.000 claims description 21
- 101001056915 Saccharopolyspora erythraea 6-deoxyerythronolide-B synthase EryA2, modules 3 and 4 Proteins 0.000 claims description 21
- 101000819248 Staphylococcus aureus Uncharacterized protein in ileS 5'region Proteins 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 244000052769 pathogen Species 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 241000711450 Infectious bronchitis virus Species 0.000 claims description 11
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 229940124551 recombinant vaccine Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims description 9
- 101710081079 Minor spike protein H Proteins 0.000 claims description 9
- 241000287828 Gallus gallus Species 0.000 claims description 8
- 108091029795 Intergenic region Proteins 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000002255 vaccination Methods 0.000 claims description 8
- 241000702626 Infectious bursal disease virus Species 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 241000725585 Chicken anemia virus Species 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 241000714474 Rous sarcoma virus Species 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 229940031348 multivalent vaccine Drugs 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000008488 polyadenylation Effects 0.000 claims description 2
- 229920000742 Cotton Polymers 0.000 claims 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 abstract description 3
- 239000013612 plasmid Substances 0.000 description 103
- 239000012634 fragment Substances 0.000 description 100
- 108091034117 Oligonucleotide Proteins 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 21
- 238000002955 isolation Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 238000010586 diagram Methods 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 101500001532 Avian infectious bursal disease virus Capsid protein VP2 Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010031571 Marek's disease virus glycoprotein B Proteins 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 108020005202 Viral DNA Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 235000013330 chicken meat Nutrition 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 5
- 101150093578 VP2 gene Proteins 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 101150034814 F gene Proteins 0.000 description 4
- 101150008820 HN gene Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 101710136297 Protein VP2 Proteins 0.000 description 4
- 206010044302 Tracheitis Diseases 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 101150029683 gB gene Proteins 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 101150027427 ICP4 gene Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- -1 etc.) Proteins 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 201000009837 laryngotracheitis Diseases 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000003844 DNA helicases Human genes 0.000 description 2
- 108090000133 DNA helicases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 101000926057 Human herpesvirus 2 (strain G) Envelope glycoprotein C Proteins 0.000 description 2
- 101000773038 Human herpesvirus 7 (strain RK) U21 glycoprotein Proteins 0.000 description 2
- 241000406668 Loxodonta cyclotis Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000010359 Newcastle Disease Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 101150015940 gL gene Proteins 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 101710130522 mRNA export factor Proteins 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 101150025032 13 gene Proteins 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101100215133 Aspergillus oryzae (strain ATCC 42149 / RIB 40) aclI gene Proteins 0.000 description 1
- 101000583080 Bunodosoma granuliferum Delta-actitoxin-Bgr2a Proteins 0.000 description 1
- 101710140962 Capsid scaffolding protein Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000653281 Enterobacteria phage T4 Uncharacterized 11.1 kDa protein in Gp30-rIII intergenic region Proteins 0.000 description 1
- 101100121779 Equine herpesvirus 1 (strain Kentucky A) gK gene Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 101150109586 Gk gene Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101001083288 Methanococcus vannielii 50S ribosomal protein L32e Proteins 0.000 description 1
- 241000701029 Murid betaherpesvirus 1 Species 0.000 description 1
- 101100293261 Mus musculus Naa15 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150082943 NAT1 gene Proteins 0.000 description 1
- 101150041636 NEC1 gene Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 101150118251 UL23 gene Proteins 0.000 description 1
- 101150060044 UL26 gene Proteins 0.000 description 1
- 101150003230 UL27 gene Proteins 0.000 description 1
- 101150104684 UL44 gene Proteins 0.000 description 1
- 101150009795 UL54 gene Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 208000011090 bird disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 101150002378 gC gene Proteins 0.000 description 1
- 101150072564 gE gene Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012345 traction test Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR96/15687 | 1996-12-16 | ||
| FR9615687A FR2757061B1 (fr) | 1996-12-16 | 1996-12-16 | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
| PCT/FR1997/002307 WO1998027215A1 (fr) | 1996-12-16 | 1997-12-15 | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001510338A true JP2001510338A (ja) | 2001-07-31 |
| JP2001510338A5 JP2001510338A5 (enExample) | 2005-03-10 |
Family
ID=9498887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52739498A Pending JP2001510338A (ja) | 1996-12-16 | 1997-12-15 | ベクターとして鳥類の感染性喉頭気管炎ウイルスを用いた鳥類用組換え生ワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6033670A (enExample) |
| EP (1) | EP0948637A1 (enExample) |
| JP (1) | JP2001510338A (enExample) |
| AR (1) | AR010086A1 (enExample) |
| AU (1) | AU734085B2 (enExample) |
| CO (1) | CO4650231A1 (enExample) |
| FR (1) | FR2757061B1 (enExample) |
| MA (1) | MA24422A1 (enExample) |
| TN (1) | TNSN97207A1 (enExample) |
| WO (1) | WO1998027215A1 (enExample) |
| ZA (1) | ZA9711247B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007512917A (ja) * | 2003-12-05 | 2007-05-24 | インフォーカス リミテッド ライアビリティー カンパニー | 改良された接眼レンズ |
| JP2013535214A (ja) * | 2010-08-02 | 2013-09-12 | ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． | 改変された伝染性喉頭気管炎ウイルス（ｉｌｔｖ）およびその使用 |
| JP2015500631A (ja) * | 2011-10-21 | 2015-01-08 | インターベット インターナショナル ベー． フェー． | 感染性喉頭気管炎ウイルスおよびニューカッスル病ウイルス抗原をコードする組換え非病原性マレック病ウイルス構築物 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07206705A (ja) * | 1993-11-03 | 1995-08-08 | American Cyanamid Co | 生インオボ（ｉｎ ｏｖｏ）ワクチン |
| WO1999018215A1 (en) | 1997-10-03 | 1999-04-15 | Nippon Zeon Co., Ltd. | Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same |
| AR031405A1 (es) * | 2000-11-21 | 2003-09-24 | Wyeth Corp | Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo |
| US7129343B2 (en) * | 2001-02-13 | 2006-10-31 | University Of Florida | Bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
| EP1241177A1 (en) * | 2001-03-15 | 2002-09-18 | Akzo Nobel N.V. | Recombinant infectious laryngotracheitis virus vaccine |
| US20030157641A1 (en) * | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| EP2022799A2 (en) | 2001-11-16 | 2009-02-11 | Biogen Idec Inc. | Polycistronic expression of antibodies |
| US20040241723A1 (en) * | 2002-03-18 | 2004-12-02 | Marquess Foley Leigh Shaw | Systems and methods for improving protein and milk production of dairy herds |
| US7083912B2 (en) * | 2002-05-31 | 2006-08-01 | Penn State Research Foundation | MAb-based Dot-ELISA method and assay kit for the detection of viruses |
| EP1606419A1 (en) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| MXPA06005424A (es) | 2003-11-13 | 2007-01-25 | Univ Georgia Res Found | Metodos para caracterizar virus de enfermedad bursal infecciosa. |
| ATE510928T1 (de) | 2004-02-19 | 2011-06-15 | Univ Alberta | Leptinpromotor-polymorphismen und verwendungen davon |
| HRP20100314T1 (hr) | 2005-04-25 | 2010-08-31 | Merial Ltd. | Cjepivo protiv nipah virusa |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| US7598364B2 (en) | 2005-11-14 | 2009-10-06 | Merial Limited | Plasmid encoding canine BMP-7 |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| CN102428099B (zh) | 2009-04-03 | 2016-03-16 | 梅里亚有限公司 | 运载新城疫病毒的禽疫苗 |
| MX344103B (es) | 2010-08-31 | 2016-12-05 | Merial Ltd | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| EP2694677A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| EP2694678A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| AU2012245395A1 (en) | 2011-04-20 | 2013-11-14 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| KR102007444B1 (ko) | 2011-04-25 | 2019-08-06 | 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 | 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물 |
| US9669085B2 (en) | 2011-06-01 | 2017-06-06 | Merial Inc. | Needle-free administration of PRRSV vaccines |
| SI2741740T1 (sl) | 2011-08-12 | 2017-08-31 | Merial, Inc. | Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv |
| US9096869B2 (en) | 2011-10-21 | 2015-08-04 | Intervet, Inc. | Recombinant nonpathogenic MDV vector providing multivalent immunity |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| WO2014081958A1 (en) | 2012-11-21 | 2014-05-30 | Cardiomems, Inc. | Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment |
| HK1216006A1 (zh) | 2013-03-12 | 2016-10-07 | Boehringer Ingelheim Animal Health USA Inc. | 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法 |
| US9198908B2 (en) | 2013-03-15 | 2015-12-01 | St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) | Methods for the treatment of cardiovascular conditions |
| CA2966191A1 (en) | 2014-11-03 | 2016-05-12 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| AR105482A1 (es) | 2015-06-23 | 2017-10-11 | Merial Inc | Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso |
| US10202582B2 (en) | 2015-06-30 | 2019-02-12 | Ceva Sante Animale | Duck enteritis virus and the uses thereof |
| EP3263129A1 (en) | 2016-06-29 | 2018-01-03 | Ceva Sante Animale | Duck enteritis virus and the uses thereof |
| CN113652406B (zh) * | 2021-09-01 | 2023-05-02 | 青岛易邦生物工程有限公司 | 一种鸡传染性喉气管炎重组病毒株及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU623913B2 (en) * | 1988-06-24 | 1992-05-28 | British Technology Group Limited | Fowlpox virus non-essential regions |
| AU633272B2 (en) * | 1988-09-13 | 1993-01-28 | Merial | Viral nucleotide sequences |
| WO1992003554A1 (en) * | 1990-08-24 | 1992-03-05 | Arthur Webster Pty. Ltd. | Infectious laryngotracheitis virus vaccine |
| FR2666589B1 (fr) * | 1990-09-07 | 1994-08-05 | Rhone Merieux | Nouveaux virus herpes recombinants, vaccin a base de ces recombinants, leur procede de preparation, genes, vecteurs et plasmides utilises dans ce procede. |
| AU7838694A (en) * | 1993-09-24 | 1995-04-10 | Syntro Corporation | Recombinant infectious laryngotracheitis virus and uses thereof |
| AU2946395A (en) * | 1994-06-30 | 1996-01-25 | Board of Regents of the University of Illinois, The | Recombinant infectious laryngotracheitis virus and vaccine |
| FR2722208B1 (fr) * | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| FR2728794B1 (fr) * | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro |
| FR2728795B1 (fr) * | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire |
| WO1996021034A1 (fr) * | 1994-12-30 | 1996-07-11 | Rhone Merieux | Vaccin vivant recombinant aviaire |
| WO1996029396A1 (en) * | 1995-03-23 | 1996-09-26 | Syntro Corporation | Recombinant infectious laryngotracheitis virus and uses thereof |
-
1996
- 1996-12-16 FR FR9615687A patent/FR2757061B1/fr not_active Expired - Lifetime
-
1997
- 1997-01-29 US US08/790,517 patent/US6033670A/en not_active Expired - Lifetime
- 1997-12-10 MA MA24897A patent/MA24422A1/fr unknown
- 1997-12-15 AR ARP970105886A patent/AR010086A1/es unknown
- 1997-12-15 WO PCT/FR1997/002307 patent/WO1998027215A1/fr not_active Ceased
- 1997-12-15 AU AU55627/98A patent/AU734085B2/en not_active Expired
- 1997-12-15 EP EP97952066A patent/EP0948637A1/fr not_active Withdrawn
- 1997-12-15 TN TNTNSN97207A patent/TNSN97207A1/fr unknown
- 1997-12-15 ZA ZA9711247A patent/ZA9711247B/xx unknown
- 1997-12-15 JP JP52739498A patent/JP2001510338A/ja active Pending
- 1997-12-16 CO CO97073364A patent/CO4650231A1/es unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007512917A (ja) * | 2003-12-05 | 2007-05-24 | インフォーカス リミテッド ライアビリティー カンパニー | 改良された接眼レンズ |
| JP2013535214A (ja) * | 2010-08-02 | 2013-09-12 | ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． | 改変された伝染性喉頭気管炎ウイルス（ｉｌｔｖ）およびその使用 |
| JP2015500631A (ja) * | 2011-10-21 | 2015-01-08 | インターベット インターナショナル ベー． フェー． | 感染性喉頭気管炎ウイルスおよびニューカッスル病ウイルス抗原をコードする組換え非病原性マレック病ウイルス構築物 |
| JP2017121250A (ja) * | 2011-10-21 | 2017-07-13 | インターベット インターナショナル ベー． フェー． | 感染性喉頭気管炎ウイルスおよびニューカッスル病ウイルス抗原をコードする組換え非病原性マレック病ウイルス構築物 |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2757061B1 (fr) | 1999-03-26 |
| TNSN97207A1 (fr) | 2005-03-15 |
| AU734085B2 (en) | 2001-05-31 |
| FR2757061A1 (fr) | 1998-06-19 |
| MA24422A1 (fr) | 1998-07-01 |
| WO1998027215A1 (fr) | 1998-06-25 |
| CO4650231A1 (es) | 1998-09-03 |
| EP0948637A1 (fr) | 1999-10-13 |
| US6033670A (en) | 2000-03-07 |
| AU5562798A (en) | 1998-07-15 |
| ZA9711247B (en) | 1999-06-17 |
| AR010086A1 (es) | 2000-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6033670A (en) | Recombinant live avian vaccine, using as vector the avian infectious laryngotracheitis virus | |
| US6153199A (en) | Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus | |
| AU735265B2 (en) | Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus | |
| AU708077B2 (en) | Live recombinant avian vaccine using an avian herpesvirus as vector | |
| US5187087A (en) | Recominbant herpesvirus of turkeys and live vector vaccines derived thereof | |
| US5853733A (en) | Recombinant herpesvirus of turkeys and uses thereof | |
| JP3972218B2 (ja) | 特に伝染性ネコ腹膜炎に対する、ネコヘルペスウイルス１型をベースとした組換え生ワクチン | |
| ES2278382T3 (es) | Herpesvirus recombinante de pavos y sus usos. | |
| US5733554A (en) | Avian herpesvirus-based live recombinant avian vaccine, in particular against Gumboro disease | |
| US5928648A (en) | Recombinant herpesvirus of turkeys and uses thereof | |
| JP4440347B2 (ja) | 組換えキメラウイルスとその使用 | |
| US5961982A (en) | Recombinant herpesvirus of turkeys and uses thereof | |
| US6913751B2 (en) | Recombinant avian herpesvirus useful in vaccine production | |
| US20100008948A1 (en) | Recombinant herpesvirus useful in vaccine production | |
| MXPA99007722A (en) | Recombinant chimeric viruses and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20040609 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20040625 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040625 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20040625 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040709 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070424 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070724 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071211 |